TABLE 2.
Prognostic factors associated with PFS.
| Variable | Univariate analysis | Multivariate analysis | ||||||
|---|---|---|---|---|---|---|---|---|
| HR | Inf 95% CI | Sup 95% CI | p | HR | Inf 95% CI | Sup 95% CI | p | |
| TMTV max at diagnosis (> 510 cm3, ref: ≤ 510) | 2.65 | 1.48 | 4.76 | 0.001 | ||||
| B2M at diagnosis (> 3, ref: ≤ 3 mg/L) | 2.59 | 1.50 | 4.47 | 6e−04 | ||||
| Score TMTV (cutoff 510 cm3) + B2M—intermediate risk (ref: low risk) | 2.79 | 1.41 | 5.53 | 0.003 | 2.50 | 1.26 | 4.96 | 0.009 |
| Score TMTV (cutoff 510 cm3) + B2M—High risk (ref: low risk) | 4.41 | 2.09 | 9.33 | < 0.001 | 3.51 | 1.62 | 7.62 | 0.002 |
| SUVmax at diagnosis (> 12, ref: ≤ 12) | 0.93 | 0.55 | 1.57 | 0.8 | ||||
| Bone marrow invasion (Yes ref: No) | 1.35 | 0.79 | 2.31 | 0.3 | ||||
| PRIMA PI—intermediate (ref: Low) | 1.38 | 0.70 | 2.7 | 0.4 | ||||
| PRIMA PI—high (ref: Low) | 2.8 | 1.45 | 5.39 | 0.002 | ||||
| Hemoglobin at time of treatment (≥ 12, ref: < 12 g/dL) | 0.40 | 0.20 | 0.80 | 0.01 | 0.46 | 0.22 | 0.97 | 0.04 |
| LDH at time of treatment (> ULN, ref: < ULN) | 1.20 | 0.59 | 2.45 | 0.6 | ||||
| Sex (M, ref: F) | 2.38 | 1.36 | 4.15 | 0.002 | 2.22 | 1.27 | 3.90 | 0.005 |
| FLIPI—intermediate (ref: Low) | 0.89 | 0.33 | 2.39 | 0.8 | ||||
| FLIPI—high (ref: Low) | 1.57 | 0.61 | 4.03 | 0.3 | ||||
Note: Values are bolded when they are considered statistically significant, meaning they are associated with a p‐value less than 0.05.
Abbreviations: B2M, beta‐2‐microglobulin; LDH, lactate dehydrogenase; TMTV, total metabolic tumor volume.